Novo Nordisk A/S
DKDKKNovo Nordisk A/S (CO:NOVO-B) — Drug Manufacturers - General. Numero di borse in cui sono quotate le azioni della società: 1. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
- Novo Nordisk A/S — NOV · XETRA DE CIK 353278 · LEI 549300DAQ1CVT6CXN342 · ISIN DK0060534915
Informazioni sull'Azienda
- Sito Web
- novonordisk.com
- Settore
- Healthcare · Drug Manufacturers - General
- Sede Centrale
- Bagsvaerd, Denmark
- Amministratore Delegato
- Maziar Mike Doustdar
- Dipendenti
- 66 700
- Quotata dal
- 06.01.2001 (CO:NOVO-B)
- Azioni in Circolazione
- 3.34 Mld
- Flottante
- 3.17 Mld
- Capitalizzazione di Mercato
- 1.08 Bln DKK
- Insider
- 5.27%
- Investitori Istituzionali
- 33.67%
- P/E
- 9.5
- Payout Ratio
- 44.6%
- FCF
- 47.8 Mld DKK
- Pagamenti / FCF
- 109%
- Debito
- 140 Mld DKK2.0 anni di FCF
- Serie di Dividendi
- 25 a.
- Utili, FCF e dividendi pagati — per i 12 mesi fino a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Borse e Ticker
| Borsa | Ticker | Valuta | Prezzo | Tipo |
|---|---|---|---|---|
| CO Nasdaq Copenhagen | NOVO-B | DKK | 248.75 -0.50% | azioni ordinarie |
Dividendi
Novo Nordisk A/S (NOVO-B) paga dividendi due volte l'anno. All'anno (12 mesi fino all'ultimo pagamento annunciato): 11.7 DKK per azione (pagamenti: 2). Questo rappresenta circa il 4.70% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 07.01.2027. Storia dei dividendi ininterrotta: 25 anni.
| Data Ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-08-18 | 3.7500 DKK | 1.3/3.9 % | semestrale | CO:NOVO-B |
| 2026-03-27 | — | 7.9500 DKK | 3.3/4.9 % | semestrale | CO:NOVO-B |
| 2025-08-15 | — | 3.7500 DKK | 1.2/3.6 % | semestrale | CO:NOVO-B |
| 2025-03-28 | — | 7.9000 DKK | 1.6/2.4 % | semestrale | CO:NOVO-B |
| 2024-08-15 | — | 3.5000 DKK | 0.4/1.1 % | semestrale | CO:NOVO-B |
| 2024-03-22 | — | 6.4000 DKK | 0.7/1.1 % | semestrale | CO:NOVO-B |
| 2023-08-18 | — | 3.0000 DKK | 0.5/1.1 % | semestrale | CO:NOVO-B |
| 2023-03-24 | — | 4.0750 DKK | 0.8/1.2 % | semestrale | CO:NOVO-B |
| 2022-08-12 | — | 2.1250 DKK | 0.5/1.4 % | semestrale | CO:NOVO-B |
| 2022-03-25 | — | 3.4500 DKK | 0.9/0.9 % | semestrale | CO:NOVO-B |
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.38% | 46.88 Mln | 2026-07-31 |
| EuroPacific Growth Fund-… | 1.07% | 36.2 Mln | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.92% | 31.13 Mln | 2026-06-30 |
| Capital World Growth & I… | 0.77% | 26.02 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 0.71% | 24.13 Mln | 2026-08-31 |
| Income Fund of America | 0.52% | 17.78 Mln | 2026-07-31 |
| Dodge & Cox Funds-Dodge… | 0.39% | 13.1 Mln | 2026-06-30 |
| Fidelity Concord Street… | 0.37% | 12.52 Mln | 2026-07-31 |
| iShares Trust-iShares MS… | 0.34% | 11.48 Mln | 2026-08-31 |
| Capital Income Builder | 0.3% | 10.32 Mln | 2026-07-31 |
| Cygnus Capital Advisors,… | 0% | 78 800 | 2026-06-30 |
| Generali Investments Cee… | 0% | 27 399 | 2026-06-30 |
| Pacer Advisors, Inc. | 0% | 24 410 | 2026-06-30 |
| Atlas Capital Advisors I… | 0% | 5 218 | 2026-06-30 |
